Modern Oncology: When Survival Is Not Enough

New therapies, “hidden” effects and the need to assess not only how long patients live, but how they live

Modern Oncology: When Survival Is Not Enough

New therapies, “hidden” effects and the need to assess not only how long patients live, but how they live

Modern oncology is changing at an unprecedented pace. Immunotherapies, antibody–drug conjugates (ADCs), bispecific antibodies and new targeted therapies are creating treatment opportunities that would have been unimaginable only a few years ago.

Cancer treatment is becoming increasingly personalised and tailored to the biological and molecular characteristics of each tumour, while overall survival is being extended for many people living with cancer.

Yet alongside this remarkable scientific progress, a critical question is emerging:

What does it really mean to live longer after — or with — cancer?

A recent Nature Medicine editorial, entitled “Oncology must confront hidden side effects”, highlights precisely this challenge. While cancer drug development is advancing at remarkable speed, the approaches used to record, assess and manage long-term treatment-related toxicities — and their impact on patients’ quality of life — have not evolved at the same pace.

When a “mild” side effect becomes a major burden

Therapeutic success can create a new reality: people are living longer, but some must also manage treatment-related adverse effects for months, years or even for the rest of their lives.

An adverse event classified clinically as low-grade is not necessarily insignificant to the person experiencing it.

A persistent rash, diarrhoea, stomatitis or other symptoms may substantially affect daily functioning, psychological wellbeing and social life when they continue over long periods.

Similarly, some immune-related adverse events associated with immune checkpoint inhibitors can become chronic, persist for years or even be irreversible.

This highlights an important limitation of the Common Terminology Criteria for Adverse Events (CTCAE), which are widely used to classify and grade treatment-related adverse events.

The duration of adverse events is not adequately reflected, while functional and psychological consequences may also remain outside traditional toxicity assessment.

As a result, what may be considered “manageable” according to conventional clinical criteria can feel very different to the patient living with it every day.

Quality of life cannot be an afterthought

A second important issue is the timing of quality-of-life evidence.

In some cases, quality-of-life findings are reported considerably later than the primary results of a clinical trial, and sometimes after a new drug has already been approved.

This means that patients making treatment decisions during the early years of a new therapy may not yet have a complete picture of how it could affect their daily functioning, emotional wellbeing and overall quality of life.

At the same time, the questionnaires and tools used to assess quality of life need to evolve continuously.

And this cannot happen without the direct involvement of patients themselves.

The experiences and priorities of people receiving treatment should form part of how treatment impact is assessed, rather than being treated as information that is added later.

The example of daraxonrasib

The Nature Medicine editorial highlights the pan-RAS inhibitor daraxonrasib as a telling example. The therapy has shown important survival benefits for patients with aggressive RAS-driven advanced pancreatic cancer, a setting in which treatment options have historically been limited.

At the same time, most patients experienced acneiform rash, with diarrhoea and stomatitis also reported as lower-grade treatment-related adverse events.

Full quality-of-life data — including information on daily functioning and emotional wellbeing — were not yet available because follow-up remained relatively short.

This example illustrates a much wider issue.

If we know that a therapy can significantly extend life, but we do not yet fully understand what that life will be like, an essential part of the information is missing from the conversation between patients and their healthcare teams.

This also has direct implications for informed consent.

Whenever evidence is available, patients need information not only about response rates and survival but also about the potential short- and long-term consequences of treatment for their everyday lives.

The same treatment is not experienced in the same way by everyone

The toxicity profile of a treatment is not identical for every patient.

It may vary according to the drug’s mechanism of action, a person’s physical condition, co-existing long-term conditions, genetic background and other individual characteristics.

Particular attention is needed for populations that have historically been excluded from, or underrepresented in, clinical trials, as their experiences of treatment-related toxicity may differ.

The editorial points, for example, to sex-related differences in adverse events associated with immunotherapy and racial disparities in adverse events observed with CAR-T cell therapy.

This makes real-world data particularly important.

Clinical trials remain fundamental to establishing the safety and efficacy of new treatments. However, broader use in everyday clinical practice may reveal treatment effects that were not fully captured in the populations included in initial studies.

One example is the bispecific antibody amivantamab in lung cancer, where the full extent and severity of some skin toxicities became clearer after a broader patient population was exposed to the treatment.

Moving beyond clinical silos

This changing landscape also demands a different approach to the organisation of cancer care.

The adverse effects of modern cancer therapies do not always fit within a single organ system or medical specialty.

Traditional clinical and disciplinary silos can limit the transfer of knowledge needed to identify, monitor and manage emerging toxicities effectively.

The response therefore needs to be interdisciplinary.

Collaborative networks, updated guidance, systematic reporting, dedicated registries and effective knowledge exchange are increasingly important so that new or rare adverse effects can be recognised early and managed appropriately.

Above all, the patient voice must be heard

Perhaps the most important change concerns how we define treatment success itself.

Survival remains a fundamental goal of oncology.

But it cannot be the only one.

We also need to understand whether people can work, move, sleep, eat, participate in family and social life, maintain as much independence as possible and manage the effects of treatment on their everyday lives.

In other words, we need to know not only how much time a treatment adds to life, but also what that time means to the person living it.

Patients should therefore not enter the process only at the end, as recipients of treatment.

Their perspectives need to be incorporated from the design of clinical trials and assessment tools through to post-approval monitoring and the real-world use of new cancer therapies.

From survival to living after — and with — cancer

Progress in oncology is undeniable, and it brings genuine hope.

The next challenge is to ensure that longer survival is accompanied by quality of life, functioning, meaningful information, participation and dignity.

Modern cancer care therefore needs to move beyond asking only:

“How much longer can this patient live?”

and give equal importance to another question:

“How will this person live during that additional time?”

For Kapa3, this discussion goes to the heart of truly person-centred cancer care: care that sees not only the disease and the treatment, but the person, their everyday life, their needs, their choices and the life that continues during and after cancer.

Source and references

Main source:
Nature Medicine. “Oncology must confront hidden side effects.” Volume 32, July 2026. Published online 8 July 2026. DOI: 10.1038/s41591-026-04554-9.

Barron CC et al. Journal for ImmunoTherapy of Cancer. 2023;11.
Gyawali B et al. Lancet Oncology. 2025;26–e89.
O’Reilly EM et al. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2605555.
Unger JM et al. Journal of Clinical Oncology. 2022;40:1474–1486.
Rayapureddy AK et al. Journal of Clinical Oncology. 2026;44.
Hines MR et al. Transplantation and Cellular Therapy. 2023;29:438.e1–438.e16.

find more s41591-026-04554-9

The Value of Pause: Why We Need to “Disconnect” Even During Treatment

Summer is often associated with the idea of holidays. Images of the sea, travel, and carefree moments fill our daily lives, creating the impression that rest requires a suitcase, a destination, and distance from obligations.

However, for cancer patients who are undergoing treatment, recovering from surgery, or waiting for test results, holidays are often not possible. Medical appointments, treatments, side effects, physical fatigue, and uncertainty about one’s health can make travelling difficult or even impossible.

And yet, the need for rest does not diminish. On the contrary, it often becomes even more important.

Perhaps, then, it is worth redefining what a “holiday” means. Not as travelling somewhere else, but as the ability to pause, even briefly, the relentless cycle of stress, worry, and constant vigilance that often accompanies serious illness. It can be a reminder that life is not only about the disease.

Rest is not a luxury — it is a need

Recent scientific literature shows that people need periods of recovery in order to maintain psychological and physical balance. Recovery is not simply “resting”; it is a process through which the body reduces the physiological and psychological burden caused by chronic stress.

In psychology, the term psychological detachment is used to describe the mental ability to step away from sources of pressure. This means allowing oneself, even for a short while, not to think constantly about what feels overwhelming.

Research by Sonnentag, Binnewies, and Mojza (2010) showed that psychological detachment is associated with lower emotional exhaustion, better mood, and greater resilience in everyday life. Similarly, Fritz and colleagues (2010) found that people who are able to mentally disengage from stress experience higher levels of well-being, energy, and functioning.

Although these studies were mainly conducted among workers, the underlying mechanism applies to every person: when the brain remains in a constant state of alert, it struggles to recover its strength.

In this sense, these small pauses matter not because they make us “forget” the illness, but because they give the brain an opportunity to step out, even temporarily, of a continuous state of alarm.

When illness takes over every thought

The experience of cancer is not limited to treatment days. It often affects everyday life as a whole. Thoughts about tests, medical decisions, bodily changes, work, family, and the future may accompany a person from morning to night.

This constant mental vigilance is exhausting in itself.

International guidelines from the National Comprehensive Cancer Network (NCCN) recognise that psychological distress is a common part of the cancer experience and recommend integrating psychosocial support into overall patient care. Likewise, guidelines from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) emphasise that mental health care and quality of life are essential parts of cancer management.

Holidays are not always about travelling

It is easy to believe that rest requires a trip. Yet scientific research suggests that the greatest benefit of holidays does not necessarily come from the destination itself, but from a change of pace and temporary distance from stressors.

Nawijn and colleagues (2010) found that people tend to feel greater well-being shortly before and during holidays, but that this feeling often fades relatively soon after they return.

This finding reminds us of something important: psychological renewal does not depend only on a few days of holiday each year, but also on the small moments of relief that we can create in everyday life.

For someone undergoing treatment, these moments may be even more valuable.

What does it mean to “pause” as a cancer patient?

To pause does not mean ignoring reality or neglecting one’s health. It means allowing oneself to remember, even for a little while, that life is not only about illness.

This may include:

a few quiet minutes on the balcony or in the garden,
a short walk in nature, when possible,
listening to favourite music,
reading a book,
engaging in a creative activity,
spending time with people who make us feel safe,
a few minutes of relaxation or mindful breathing, when appropriate for one’s health condition.

These moments do not change the diagnosis. But they can change the experience of the day.

The importance of quality of life

In modern oncology, quality of life is now considered a key therapeutic goal. Treating the disease is not enough; it is equally important for the person to maintain as much functionality, autonomy, emotional balance, and sense of meaning as possible.

This importance is also reflected in the value framework for cancer treatments developed by the American Society of Clinical Oncology (ASCO). According to this framework, the value of a treatment is not determined solely by its effectiveness, but also by its toxicity, its impact on quality of life, and the personal priorities and preferences of the patient.

This highlights the importance of personalised, patient-centred care, in which the person’s everyday experience is an essential part of the therapeutic process.

Within this perspective, small moments of pause, the continuation of pleasant activities, and connection with what brings joy are not secondary aspects of life. They are meaningful elements that contribute to preserving quality of life. They are not luxuries, signs of weakness, or attempts to avoid reality. They are forms of self-care.

The same applies to family caregivers, who often experience high levels of emotional and physical burden. Taking some time for their own rest is not selfishness; it is a necessary condition for continuing to support their loved one in a meaningful way.

The value of a small pause

The experience of cancer often extends beyond the limits of the disease itself, affecting a person’s self-image, social roles, and daily life. Intense psychological distress and uncertainty can gradually allow the illness to occupy more and more space in life.

In this context, psycho-oncological education appears particularly important. Its aim is to help patients and family caregivers understand the emotional reactions that naturally accompany diagnosis and treatment, develop more effective coping strategies, and actively participate in treatment decisions.

In this way, the sense of control and self-efficacy is strengthened, while also preserving the sense that a person remains something more than their illness.

When health does not allow for travel, it is easy to feel deprived of something important. Yet perhaps the essence of a holiday lies not in the distance we travel, but in the distance we allow ourselves to take from stress.

To “pause” does not mean to stop being a patient. It means allowing oneself, even for a little while, to be something more than the illness.

Perhaps, in the end, the most meaningful holidays are not those that take us far from home, but those that allow us to rest the body, calm the mind, and turn toward ourselves with greater care.

A peaceful sunlit balcony with a chair, a book, a cup, flowers, and an olive tree, illustrating the importance of small moments of rest and self-care during cancer treatment.

By Marilia Barka
Psychology Student
Kapa3 Volunteer

June: Cancer Survivors Month

Survival is a victory — but care must continue

June is dedicated to people living with and beyond cancer. It is a month of recognition, hope and respect for every person who has faced a cancer diagnosis, completed treatment, continues treatment, or lives with cancer as a long-term condition.

Cancer survival is a major victory. However, for many people, it is not the end of the story. Life after cancer often brings a new reality: follow-up appointments, fear of recurrence, fatigue, emotional distress, changes in body image, work-related challenges, financial pressure, family adjustments and the need to rebuild everyday life with confidence and dignity.

Cancer Survivors Month reminds us that survivorship is not only about living longer. It is also about living better.

A cancer survivor is not only a person who has completed treatment and is disease-free. The term also includes people receiving maintenance treatment, people living with cancer as a chronic condition, and those who continue to experience the physical, emotional, social or economic consequences of the disease and its treatment.

In recent years, advances in early diagnosis, targeted therapies, immunotherapy, surgery, radiotherapy and supportive care have increased the number of people living many years after a cancer diagnosis. This is a major achievement for medicine, research and public health. At the same time, it creates a new responsibility: to ensure that survivorship care is organised, person-centred and accessible to all.

For many survivors, the end of active treatment is a moment of relief and gratitude. Yet it may also bring uncertainty. Some people feel that everyone around them expects them to “go back to normal”, while they are still trying to understand what has changed in their body, their emotions, their relationships and their daily life.

The fear of recurrence, anxiety before follow-up tests, persistent fatigue, pain, cognitive difficulties, changes in sexuality, emotional vulnerability and social isolation are real experiences for many people after cancer. These needs should not be underestimated. Survivors need space to speak, reliable information, access to professional support when needed, and connection with communities and organisations that understand their journey.

Long-term follow-up is also essential. Survivorship care should not focus only on recurrence. It should also include prevention, early recognition of late effects, management of treatment-related complications, support for mental health, healthy lifestyle guidance and personalised monitoring according to each person’s cancer type, treatment history, age and individual risk factors.

The message is not fear. The message is awareness, prevention and continuity of care.

Life after cancer is also about rights. It is about returning to work, accessing social benefits, understanding available services, managing financial toxicity, supporting caregivers, protecting dignity and ensuring equal access to care. Survivorship must be seen as a social, psychological and practical issue — not only a medical one.

At Kapa3, we see every day that cancer does not always end with the last treatment. It continues in the questions people ask about their rights, their next steps, their follow-up, their access to benefits, psychological support, work, family life and social reintegration.

This is why people living with and beyond cancer need holistic support. They need information, guidance, psychosocial care, access to rights and services, empowerment and continuity of care. No one should feel alone after treatment. No one should be left to navigate bureaucracy, uncertainty or lack of information without support.

Cancer Survivors Month invites us to change the way we talk about survival. We should not ask only: “Did the person survive cancer?” We should also ask:

Are they living with quality of life?
Do they have access to the care they need?
Do they know their rights?
Do they receive psychological and social support?
Can they return to work and daily life with dignity?
Is there a follow-up plan?
Is there someone to guide them when they do not know where to turn?

Cancer survival is a victory. But the real challenge is to turn this victory into a life with quality, safety, rights, support and hope.

At Kapa3, we continue to stand beside every person living with and beyond cancer. Through information, guidance, empowerment and human-centred support, we believe that care does not stop at treatment.

It continues in life.

MELODIC Online Symposium: completion of the pilot training phase and strengthening psychosocial cancer care

The European project MELODIC (Mental Health Support for Young Adults with Cancer), in which the Cancer Guidance Center – Kapa3 participates, is being implemented through distinct development phases. The pilot training programme for healthcare professionals is one of its core components, and within this framework, the MELODIC Online Symposium 2026, taking place on 24 April 2026, marks the completion of this educational phase.

The MELODIC project framework

MELODIC is a European project co-funded by the European Union, aiming to strengthen the mental health of young adults living with cancer, as well as to support their families. Through the collaboration of universities, research institutions and healthcare organizations across Europe, the project develops training and support tools for healthcare professionals.

More information about the project and its progress is available on the official Kapa3 website, in the dedicated project section.

The pilot training programme

The pilot training programme focused on enhancing the knowledge and skills of healthcare professionals in providing psychosocial support to young adults with cancer and their families.

As part of the programme, online sessions and contact lessons were delivered, aiming to strengthen interdisciplinary collaboration and support the practical application of tools in everyday clinical practice.

MELODIC Online Symposium 2026

The MELODIC Online Symposium 2026, a two-hour event, brings together participants from all partner countries and includes:

opening presentations from the European Cancer Organisation and Youth Cancer Europe
an “experts by experience” panel, where individuals share their lived experience
a networking panel with healthcare professionals from participating countries
discussion on how training can be applied in clinical practice
a closing session by the project coordination team

From training to clinical practice

A key objective of the MELODIC training programme is to strengthen the psychosocial dimension of cancer care, with particular focus on young adults.

The exchange of experiences among healthcare professionals contributes to more holistic approaches to care and supports the integration of psychosocial support into daily clinical practice.

The role of Kapa3

Kapa3 actively participates in the European MELODIC consortium, contributing to the implementation of the training activities and the dissemination of results in Greece. Through this involvement, the connection between scientific knowledge and the support of cancer patients is further strengthened, promoting the development of practical approaches to psychosocial care.

The MELODIC Online Symposium 2026 marks the transition from the pilot training phase to the next stage of utilizing its outcomes, reinforcing the link between education and real-world application in cancer care.

The Press Release here: PRESS-RELEASE-MELODIC SYMPOSIUM

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Kapa3 and Karkinaki join forces to support children, adolescents, and families living with cancer

The Cancer Guidance Center – Kapa3 announces its new collaboration with the non-profit organization “Karkinaki”, aiming to strengthen information, psychosocial support, and awareness around childhood and adolescent cancer, as well as to support families experiencing the disease.

Karkinaki is a specialized organization working in the field of childhood and adolescent cancer, focusing on reliable information, empowering parents and caregivers, and fostering a supportive environment around children and teenagers affected by cancer. Through community-based actions and awareness initiatives, it seeks to reduce the sense of isolation that often accompanies diagnosis, while also enhancing understanding, social awareness, and access to available support resources for families.

Within the framework of this collaboration, the two organizations will develop joint initiatives focused on information and awareness-raising, with an emphasis on actions addressing both families and healthcare and support professionals. The partnership will also include the co-organization of informational events, the exchange of good practices, and the exploration of participation in national and European programs that promote a holistic approach to patient care, with an emphasis on continuity of support across all stages of the disease experience.

The Cancer Guidance Center – Kapa3 is dedicated to informing, guiding, and empowering people affected by cancer, providing practical support and access to reliable information and services. At the same time, it develops initiatives that strengthen patients’ active participation in managing their health and promotes a more accessible and human-centered model of care.

In this context, Kapa3 is also involved in European collaborations focusing on the psychosocial dimension of cancer across different stages of life, such as the MELODIC project, which addresses the mental health of young adults with lived experience of cancer. This work further enhances the organization’s ability to recognize needs that emerge throughout the cancer journey, from childhood to adulthood.

This collaboration with Karkinaki reflects the shared vision of both organizations to strengthen a support network that goes beyond medical treatment, extending into families’ daily lives, information access, and psychosocial empowerment, with the aim of providing a more stable and meaningful presence for those who need it most.

Our Press Release here: KARKINAKI PRESS RELEASE

Text: Ifiyenia Anastasiou for Kapa3

Cancer: From Prevention to Life Coordination – Successful Knowledge Seminar in Megara with Kapa3

With great success and participation from citizens of all ages, the Knowledge Seminar in Megara – From Prevention to Life Coordination took place on Sunday, February 8, in the Council Chamber of the Megara City Hall, in celebration of World Cancer Day.

The event was organized by the Municipality of Megara in collaboration with the Kapa3 Cancer Guidance Center, which since 2020 provides guidance and support to oncology patients and their families, ensuring access to vital information and services.

The seminar opened with a speech by the Mayor of Megara, Panagiotis Margetis, who shared his family’s personal experience with cancer, emphasizing the importance of accurate information and support throughout the patient journey. Stamatis Georgakis, Deputy Mayor for Public Health and Social Protection, coordinated the seminar and highlighted the value of Kapa3 and its Guidance Station in informing, supporting, and advocating for patients’ rights.

Distinguished experts participated in the seminar, presenting key aspects of holistic cancer care:

Georgios Nintos, MD MSc, Oncologist: Prevention and early diagnosis, causes, and preventive measures.
Katerina Papakonstantinou, MD MSc PhD, Obstetrician-Gynecologist: Gynecologic cancer, importance of HPV vaccination and Pap test.
Andrea Paola Rochas, Assistant Professor of Biology, University of Peloponnese Nursing Department: Nutrition and cancer prevention, emphasizing the Mediterranean diet, exercise, and avoidance of processed foods.
Maria Lavdaniti, Professor and Head of Nursing Department, International University: Role of oncology nurses in holistic care.
Pinelopi Vlotinou, Assistant Professor of Occupational Therapy, University of West Attica: Daily living support and quality-of-life improvement through occupational therapy.
Ioanna Sideri, Psychologist MSc, PhD(c), University of Peloponnese: Psychological support for patients and caregivers, resilience, and crisis management.
Grigoria Zacharogianni, MD MSc PhD, Radiation Oncologist: Modern treatment options and importance of moderate exercise during therapy.

The presentation of Kapa3 was delivered by Evangelia Bista, Co-founder and Head of Strategic Partnerships, highlighting the importance of digital literacy and a holistic approach to patient care. Kapa3 has expanded its oncology support network by inaugurating the Cancer Guidance Station in Megara, with the significant support of Megara Resins. In its first year, the station has assisted over 100 beneficiaries, offering guidance on social rights, patient file management, and psychological support, free of charge.

For 2026, Kapa3 is strengthening its digital services with Myrto, Greece’s first AI-powered Health Digital Assistant, providing personalized guidance and voice control. Planned initiatives also include: Wellness in Motion, with 12 outdoor walks for mental wellbeing of young adult cancer patients, the Cancer Wellness Open House Day, and a conference on equitable access to care.

The Knowledge Seminar in Megara – From Prevention to Life Coordination highlighted the importance of prevention, holistic care, interdisciplinary collaboration, digital literacy, psychological support, and continuous patient rights education.

Kapa3 warmly thanks the Municipality of Megara for hosting and supporting the event, as well as all speakers, for their invaluable expertise and commitment to sharing knowledge and scientific know-how.

Explore the photo gallery here:

The Press Release document here

The MELODIC Consortium met in Athens to promote the mental health of young adults with cancer

We were delighted to welcome the European partners of the MELODIC Consortium in Athens, during the two-day consortium meeting held on 19–20 January 2026, at the facilities of the School of Public Health, University of West Attica (UNIWA).

Representatives from all participating countries – Finland, Estonia, the Netherlands, Portugal, and Ireland – attended in person, while there was also significant active online participation. The excellent organization and warm hospitality created a collaborative and open communication environment, boosting optimism around the successful progress of the project.

On the first day, discussions focused on the progress of WP2 and WP3, including publication planning, needs assessment, and the development of the educational curriculum for healthcare professionals, aiming to support the mental well-being of young adults with cancer experience and their families.

In this context, the importance of approaches linking physical activity, natural environments, and mental health was highlighted, recognizing nature as a space for recovery and meaningful experiences for young people who have undergone demanding treatments.

During the short breaks, participants had the opportunity to meet and exchange views on the challenges and best practices in the field of mental health for young adults with cancer.

Later in the afternoon, participants enjoyed a lovely dinner at Iamvos Restaurant, located in the historic neoclassical building “Kostis Palamas” of the National and Kapodistrian University of Athens, in a welcoming atmosphere that encouraged networking and human interaction.

On the second day, the work continued with the further development and evaluation of the MELODIC intervention (WP4), with particular emphasis on the blue and green spaces as a key component of its design, followed by discussions on the communication, dissemination, and sustainability strategy (WP5), as well as project management and quality assurance (WP1).

Partners actively participated, exchanging knowledge and experiences, and planning the next steps of the collaboration, while later braving the chilly weather for the optional visit to the Stavros Niarchos Foundation Cultural Center, where they admired the National Library, the National Opera, and the blue and green spaces of the foundation, combining nature with inspiration.

Kapa3’s participation in the MELODIC Consortium ensures that the voices of young adults with cancer experience and their families are considered at every stage of the project.

We look forward to continuing our close collaboration with our European partners, preparing the next phase of the project and disseminating its results, aiming to enhance the mental health and overall well-being of young adults with cancer across Europe.

More information about the project can be found here.

Download our Press Release in pdf or word

Text/adaptation: Ifiyenia Anastasiou for Kapa3

The Visit of Love: a shared act of care and hope

In December 2025, Kapa3 took part once again the Visit of Love, an initiative by WinCancer that aims to bring warmth, presence, and emotional support to those who will spend the holiday season in oncology hospitals.

Once again, the response was deeply moving.

Cards and messages arrived from all over — through the post, by courier, in parcels both large and small, and sometimes delivered by hand. Each one carried a simple but powerful message: you are not alone.

Among them were cards written by preschool children, some with their very first letters, others expressed through drawings and colours. Messages full of innocence, light, and hope — “get well so we can eat Christmas cookies together.”

There were also messages from adults who had faced cancer in the past and now shared their words of encouragement together with their children, closing a circle of empathy and solidarity.

This action is addressed to everyone who will spend the holidays in oncology hospitals — patients, companions, and healthcare professionals alike — acknowledging the emotional weight of these days and the importance of human connection.

The process was intense, emotional, and, at times, chaotic.

Glitter and golden dust filled desks, clothes, and hair. While those traces will eventually disappear, the love, smiles, and hope that passed through our hands will remain.

For Kapa3, supporting initiatives like the Visit of Love is an essential part of our mission: to strengthen collaboration, promote solidarity, and contribute to actions that place human connection at the centre of care.

We warmly thank WinCancer for the trust and collaboration, as well as everyone who participated and offered a piece of their heart. Together, we can continue creating moments that matter.

Until next year, we hold on to the love, the hope, and the reminder that small gestures can make a big difference.

Text: Ifiyenia Anastasiou for Kapa3

GD2: A Critical Biomarker and Therapeutic Target – What the Latest Evidence Shows

New scientific data highlight GD2 — a glycolipid biomarker expressed in specific cancer cells — as one of the most promising therapeutic targets in modern oncology. A recent review published in an international scientific journal brings together the latest findings on the use of GD2 in immunotherapies, CAR-T cell treatments, monoclonal antibodies, and other innovative approaches.

What is GD2 and why does it matter?

GD2 is a molecule known as disialoganglioside-2, found in high concentrations on the surface of certain cancer cells. This makes it particularly valuable as a target for personalized immunotherapies, as treatments can “recognize” and destroy GD2-positive cells while sparing healthy tissues.

Cancers with high GD2 expression include:
• Neuroblastoma
• Osteosarcoma
• Melanoma
• Breast cancer (triple-negative in some cases)
• Certain lung cancers
• Rare pediatric tumors

In neuroblastoma — one of the most common pediatric cancers — GD2-directed antibody therapy has already improved survival in high-risk patients.

The new scientific review maps the current progress in GD2-targeted therapies, highlighting the technologies showing the strongest clinical potential. GD2-directed monoclonal antibodies, already effective in children with neuroblastoma, are evolving into more precise and safer versions, aiming to expand their use in adult tumors as well. The review also presents updated data from clinical trials of GD2-directed CAR-T cells: despite challenges such as toxicity, tumor escape, and limited persistence, newer CAR-T generations demonstrate improved safety, deeper penetration into solid tumors, and especially promising outcomes in pediatric patients.

The review further examines combination immunotherapies that pair GD2 targeting with radiotherapy, chemotherapy, or immune checkpoint inhibitors, offering enhanced effectiveness against resistant tumors. Finally, emerging platforms are described — including bispecific antibodies, “smart” nanoparticle-based strategies, and drug-delivery technologies that target only GD2-positive cells — expanding the therapeutic landscape and opening new avenues for future applications.

What does this mean for patients?

GD2-targeted therapy is no longer theoretical — it is already a reality in certain pediatric cancers and is rapidly expanding into other tumor types.

Key benefits for patients include:
• greater precision with reduced toxicity
• the potential for highly individualized treatment based on tumor profile
• new hope for tumors that remain difficult to treat with existing methods
• improved survival prospects, especially for children

For pediatric and young adult patients — a group with historically limited and often highly burdensome treatment options — GD2-directed therapies represent a significant step forward.

Despite the important progress made, several challenges remain. These include side effects such as neuropathic pain, tumor resistance or escape from targeting, the high cost and limited availability of advanced treatments, and the need for large, multi-center clinical trials to produce more robust and generalizable data. Still, research activity is intensifying, with dozens of clinical studies currently ongoing worldwide.

Within this evolving landscape, Kapa3 remains committed to providing accurate, accessible, and compassionate information to patients and families, particularly those facing severe, rare, or pediatric cancers. Advances in GD2-targeted therapies are opening new pathways for children and young people with limited options today , showcasing the power and potential of immunotherapy. At the same time, they highlight the urgent need for equitable access to innovative treatments for patients in Greece.

Kapa3 will continue to follow scientific developments closely and keep the community informed in a clear, reliable, and human-centered way.

Sources: Here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

World AIDS Day — December 1

World AIDS Day is a powerful reminder that the fight against HIV/AIDS is far from over. Despite remarkable progress in recent decades, millions of people worldwide are still living with the virus. At the same time, inequalities in access to prevention, diagnosis and treatment continue to cost lives.

Established in 1988 as the first international health-related awareness day, World AIDS Day has since served as a global call for informed action, early diagnosis, destigmatization and equitable care.

What We Know Today About HIV/AIDS

According to recent UNAIDS data, more than 39 million people are living with HIV globally — and thanks to modern treatments, they can live full and healthy lives.

The science is encouraging. Antiretroviral therapy (ART/ARVs) allows people on treatment to reach undetectable viral loads, which means they cannot transmit the virus (“Undetectable = Untransmittable”).

Yet despite this progress, new infections still occur — mainly in communities facing social exclusion, economic hardship, or limited access to healthcare services. At the same time, lack of information and persistent stigma remain major barriers that delay testing and treatment.

HIV & Cancer: An Important Connection

The link between HIV and several forms of cancer isn’t widely known, yet it is significant:

People living with HIV have a higher risk of cervical cancer due to the more persistent presence of HPV.
Increased risk is also observed for non-Hodgkin lymphoma, Kaposi sarcoma and several cancers associated with chronic viral infections.
Early diagnosis, continuous treatment and regular screening significantly reduce these risks.

At Kapa3, we have published articles on the importance of screening and patient empowerment, which you can find here: Article1, Article2, Article3, Article4, Article5.

The Situation in Greece

Greece has made important progress in recent years, thanks to the operation of Checkpoints, the support of NGOs and prevention structures, the spread of PrEP, and improved access to treatment.

In 2024, Greece recorded a small decrease (4%) in new HIV diagnoses compared to 2023, according to the Hellenic National Public Health Organization (EODY). However, underdiagnosis remains a real concern. Many people avoid timely testing due to stigma and fear of discrimination.

Prevention: What Each of Us Can Do

Testing: a simple test can save lives.
Condom use & comprehensive sexual education.
PrEP & PEP: modern and effective prevention tools.
Eliminating stigma: information and open dialogue remain our strongest forms of protection.
Supporting facilities that provide access to prevention, diagnosis and treatment.

A Human Rights Issue

At Kapa3, we believe World AIDS Day concerns all of us. Access to healthcare is a fundamental right. No one should be afraid to get tested, speak openly or seek support.

According to International Human Rights Law, discrimination based on HIV status, sexual orientation, gender identity or expression, health status (including substance use), or sex work constitutes a violation of human rights.

World AIDS Day reminds us that knowledge, prevention and solidarity save lives — and that a world without new HIV infections is possible.

Sources

UNAIDS
HIV.gov
AIDS Healthcare Foundation
EODY (Hellenic National Public Health Organization)

Text/Adaptation: Ifiyenia Anastasiou for Kapa3